ESS Tech

Phase A — Understand the business

Company Overview

What it is. ESS Tech, Inc. is "a long-duration energy storage company specializing in iron flow battery technology… designed and produced predominantly using earth-abundant materials" that the company believes "can be cycled over 20,000 times without capacity fade based on lab-scale results". The electrolyte is primarily salt, iron and water — non-flammable, no thermal-runaway risk, no lithium/cobalt/vanadium supply exposure. The pitch is 4–12+ hour long-duration energy storage (LDES) for grid stabilization, peaker-plant replacement, and commercial/industrial sites.

Corporate history. Legacy ESS went public via SPAC (ACON S2 Acquisition Corp) in October 2021; the successor entity is ESS Tech, Inc. (merger completed 31-Mar-2024). Incorporated in Delaware; HQ 26440 SW Parkway Ave., Wilsonville, OR; Commission file 001-39525; CIK 0001819438. Listed on NYSE as common GWH and warrants GWH.W.

Products — and a telling product retreat. The original commercial products were the Energy Warehouse (container-scale) and Energy Center (larger). The company states plainly: "Our original product offering included the Energy Warehouse and Energy Center, which we are not currently offering for sale" — it now only performs warranty/maintenance on the installed base of those generations. The current focus is the "Energy Base" gigawatt-hour-scale product plus core power-train components shipped for site assembly — but the filing concedes "Production and productized versions of our Energy Base product and core component technology are still under development," and "we have experienced various quality and performance issues with units that have been installed". Read this carefully: after ~14 years and three product generations, the company has discontinued the only two products it ever sold and the replacement is still not productized. That is the central fact about this business.

The 2026 sodium-ion pivot (post-period, material). On 23-Jun-2026 ESS announced it will "accelerate development of sodium-ion battery energy storage systems" via a letter of intent with Alsym Energy, while "continuing development of its iron flow battery technology for long-duration applications" and "streamlining its Wilsonville operations… to reallocate capital toward sodium-ion… with greater near-term revenue potential". The earlier framework (late-Apr 2026) contemplated up to 8.5 GWh of Alsym sodium-ion cells/modules added to ESS's portfolio targeting data centers, utilities and critical infrastructure. Management claims "early-stage opportunities approaching $1 billion" for sodium-ion — pipeline language, not orders.

Customers / contract structure. Revenue is contract-by-contract project sales (deferred-revenue recognized on acceptance), not recurring. The installed base is tiny: "As of December 31, 2025, we had limited Energy Warehouse and Energy Center products fully deployed". Related-party commercial relationships with SB Energy (SoftBank affiliate) and Honeywell anchor much of the historical pipeline. The flagship 2026 win is a $9.9M AFRL/Concurrent Technologies contract (announced 29-Jan-2026) to deploy up to 27 MWh of iron-flow storage at the U.S. Clear Space Force Station in Alaska, valued for operation below −40°C — a genuine, defensible niche use case, but demonstration-scale.

Supply Chain

Map: upstream raw inputs → ESS → integrator/EPC → end customer (utility / C&I / defense / data center).

• Upstream (iron-flow): earth-abundant inputs — iron salt electrolyte, water, plastics/membranes, balance-of-system (pumps, power electronics, containers). The core differentiator is deliberately commodity inputs (no lithium/cobalt/nickel/vanadium), which removes critical-minerals chokepoints that bind lithium and vanadium-flow rivals. Counterweight: the bottleneck is not materials, it is manufacturing yield and field reliability — the "quality and performance issues" admission is the real chokepoint.
• Upstream (sodium-ion, new): ESS does not own the cell chemistry — it sources from Alsym Energy, which in turn relies on Re:Build Manufacturing (MOU, Jun 2026) to build U.S. sodium-ion cell capacity. This inserts two external single points of dependency (Alsym IP + Re:Build fab) directly into ESS's most-promoted future product line. Alsym is also non-exclusive to ESS — it has separately signed Juniper Energy for 500 MWh of grid storage. ESS is one channel among several for a supplier's product.
• ESS itself: Wilsonville, OR assembly; two EXIM-financed production lines (financing facility, see Lens 5) intended to scale Energy Base — undercut now by the capital reallocation toward sodium-ion.
• Downstream: SB Energy / Honeywell (related parties), AFRL/CTC (defense), and the targeted data-center/utility buyers for sodium-ion. Standby letter of credit ($0.6M with Bank of America) secures one customer agreement.

Chokepoints: (1) ESS's own manufacturing/reliability is the binding constraint on iron-flow; (2) the sodium-ion line is wholly dependent on a third party's chemistry and a third party's fab — a supply chain ESS neither owns nor controls. Names present; lens passes.

Competitive Advantages (moats)

Claimed moats. (1) Earth-abundant, non-flammable chemistry — no lithium fire risk, no critical-minerals exposure, ~25-year design life, claimed 20,000-cycle durability with no capacity fade (lab-scale). (2) ~50 years of iron-flow R&D and a patent estate around solving the historical hydroxide/electrode-clogging problem. (3) Extreme-environment performance (operation below −40°C) — the basis of the AFRL/Alaska award.

Reality check on the moat. The moat is technological promise unconverted to commercial advantage. A durable moat must protect economic profit; ESS earns deeply negative gross profit and has discontinued its only sold products. Switching costs, network effects, and scale economies are all absent because there is essentially no installed fleet to lock in and no volume to drive a cost curve. Bargaining power is negative on both sides: ESS needs customers far more than they need it (any buyer can choose lithium, zinc, or vanadium alternatives), and on the new sodium-ion line it is a price-taker dependent on Alsym. The genuine, narrow moat is the defense/harsh-environment niche (extreme cold, non-flammability, energy security) — real but small. Ground: positioning.md/bottlenecks.md are missing for the energy beat; assessment is from the 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. + competitive landscape.

Segments

Single operating segment. "The Company operates as a single business operating segment… all activities related to the design, engineering, and manufacturing of the Company's long-duration energy storage systems," with the CEO as CODM (our figures is empty by design — there is nothing to disaggregate). Geographically the company sells into U.S. and international (Europe/Australia via SB Energy) markets, but volumes are immaterial. The only meaningful "segmentation" going forward is the emerging iron-flow (LDES) vs. sodium-ion (short-duration/data-center) split — and the 2026 strategy is explicitly to shift capital from the former to the latter. Trend: revenue decelerating to near-zero ($6.3M → $1.6M, −75% YoY), so there is no growth mix to analyze, only a contraction.

---

Phase B — Measure performance

Earnings Result

FY2025 income statement:

The single most important number: gross loss of $(27.7)M on $1.6M of revenue — ESS spent ~$29.3M to produce ~$1.6M of product, i.e. cost of revenue was ~18× revenue. Gross margin ≈ −1,748%. There is no operating-leverage story until this inverts; every unit shipped today consumes cash before a dollar of opex.

Q1 2026 (latest print):

• Revenue: ~$0.1M (immaterial; ).
• Net loss: $(15.9)M; cash used in operations $(13.5)M.
• Liquidity 31-Mar-2026: $21.5M ($15.5M cash + $6.0M short-term investments).
• Stockholders' equity: $9.4M; total liabilities $39.1M; accumulated deficit $(861.7)M.

Balance-sheet flags. Cash + ST investments $22.0M at 31-Dec-2025 → $21.5M at 31-Mar-2026 → ~$13.6M at 31-May-2026. The ~$0.5M sequential "stability" into Q1 was manufactured by issuance, not operations: FY2025 financing inflow $43.5M and Q1-2026 raised ~$22.8M gross via ATM/RDO/financing arrangements. Debt is otherwise minimal — the EXIM facility was largely undrawn ($0 at year-end; ~$9.2M financing-arrangement proceeds drawn in Q1).

Market reaction. Q1 print 2.7% lower — muted because distress was already in the price. The stock sits at $0.76–0.85 (late-Jun 2026) versus a 52-week range of $0.567–$13.78.

Unusual vs. own history: the revenue decline in a year the LDES TAM is growing is the anomaly — peers are scaling into the same demand (Eos guiding $300–400M FY2026), while ESS contracted.

Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty; our model not run for GWH). From public commentary and press releases, the management narrative arc over the last ~18 months is itself the signal:

• 2024: "scaling Energy Base / Energy Center, EXIM financing two production lines" — a manufacturing-scale story.
• Early 2025: CEO departure (Eric Dresselhuys separated Feb-2025), interim leadership, cost cuts, furloughs (including accounting staff) — a survival story.
• Late-2025 → 2026: capital-markets CEO installed, discontinuation of Energy Warehouse/Center, then the sodium-ion/Alsym pivot — a re-positioning toward a fundable narrative (data centers, $1B "opportunities," non-flammable safety).

The tone has shifted from "scale the product" to "survive and find a story the capital markets will fund." The recurring new phrases — "data centers," "near-term revenue," "streamlining," "cash conservation" — and the dropped phrases — "Energy Warehouse," "production-line ramp" — tell the whole story. (Sentiment assessment is -derived; flagged as not transcript-grounded.)

Comps

LDES / grid-storage peers. Multiples are revenue-light or n/m because most of this cohort is pre-profit; market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth. and revenue are the honest comparators.

The comp that matters: ESS at ~$10M market cap is two-to-three orders of magnitude below Eos ($1.76B) and Energy Vault ($530M), and an order of magnitude below even Invinity, its direct vanadium-flow analog. The market is not pricing ESS as an LDES growth equity at all — it is pricing it as a near-failed enterprise worth roughly its remaining cash (~$13.6M). Per-share multiples are not meaningful against losses; n/a where a credible multiple cannot be cited (do not fabricate).

Stock-Price Catalysts (what moves >5%)

Pattern over the public history:

• Going-concern / liquidity headlines — the dominant down-driver. Each 10-K/10-Q reiterating substantial doubt, and the cash-burn cadence, has compounded a draw-down from a 52-week high of $13.78 to sub-$1.
• NYSE deficiency notices — 24-Mar-2025 (sub-$50M market cap + sub-$50M equity) and 9-Jun-2026 (sub-$1.00 average share price); both depress and add reverse-split/delisting overhang.
• Dilution events — ATM/RDO issuances (share count 12.0M → 22.4M → 27.9M across FY25→Q1-26, plus 4.35M pre-funded warrantsPre-funded warrantA right to buy shares that has already been paid for, bar a token penny. It behaves like a share the investor already owns, so leaving it out of a share count understates the company’s real size.) are structural down-pressure.
• Strategy/contract catalysts (the up-spikes): the $9.9M AFRL/Alaska contract (29-Jan-2026) and the Alsym sodium-ion pivot (Apr/Jun-2026) produced relief rallies on "data-center" and "$1B pipeline" framing.

What the tape reveals: this name trades on survival probability and narrative, not earnings. It reacts violently to (a) anything touching the financing runwayRunwayHow long the cash lasts at the current rate of spending. It shortens the moment spending rises, which is why a figure taken from a quiet quarter flatters. and (b) any headline that reframes it as a fundable AI/data-center story. Short interestShort interestHow many shares have been borrowed and sold by people betting the price falls. is only ~6.6% — so this is not primarily a short-driven decline; it is dilution and fundamentals.

---

Phase C — Judge people & books

Management

• CEO: Drew Buckley (effective 1-Jan-2026; signed the FY2025 10-K as Principal Executive Officer ). Background: ~17 years at William Blair as a Partner focused on small/mid-cap technology investing; joined ESS in Aug-2025 "to lead the company's investor relations and capital market strategy," then elevated to CEO. This is the single most diagnostic governance fact in the dossier. A company in product crisis that elevates a capital-markets/IR specialist to CEO is telling you, unambiguously, that its binding problem is financing survival, not engineering or commercialization. The mandate is to keep the equity raise alive and find a narrative the market will fund — which is exactly what the sodium-ion/data-center pivot delivers.
• CFO: Kate Suhadolnik (promoted from interim, Jan-2026). CSO/GC: Kelly Goodman (former interim CEO).
• Predecessor: Eric Dresselhuys separated 13-Feb-2025 — the operating CEO who oversaw the failed Energy Warehouse/Center commercialization.
• Track record: the incumbent operating team did not deliver commercial scale — three product generations, two discontinued, $846M accumulated deficit, revenue contracting. The new CEO has no operating/manufacturing track record at all — his record is in capital markets.
• Skin in the game: insider ownership is modest; the dominant economic stakeholders are the SPAC legacy holders and strategics (SoftBank/SBE, Honeywell warrants). No our figures on the shelf.
• Capital allocation: value-destructive by the only available metric — ROE/ROIC are deeply negative and the equity has been serially diluted to fund operating losses. The EXIM production-line capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. is now being reallocated away mid-stream (toward sodium-ion), which is itself a sign the prior capital plan was wrong.
• Archetype: professional turnaround/capital-markets manager, not founder-operator. For this stage that implies the playbook is financial engineering + narrative repositioning + cost cuts, not a patient product ramp.

Forensic Red Flags

• Going concern (explicit, both filings): "There is substantial doubt about our ability to continue as a going concern" — for ≥12 months from each filing date. This is the headline forensic fact and it is disclosed, not hidden.
• Negative gross margin (~−1,750%): cost of revenue (~$29.3M) dwarfs revenue ($1.6M) — the unit economics are broken at the gross line, before any opex.
• Cash vs. earnings: operating cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits. $(50.3M) FY2025 / $(13.5M) Q1-2026 tracks net loss closely (net loss $(63.4M)/$(15.9M)); the gap is non-cash D&A ($5.7M FY25), SBC ($5.4M FY25), and non-cash interest — i.e. losses are real cash losses, not accounting artifacts. No earnings-quality games here; the problem is the cash itself.
• Stock-based compensation: $5.4M FY2025 (down from $11.6M FY2024) — material relative to a $1.6M revenue base but trending down with headcount cuts; a dilution contributor, not an earnings-flattering device (the company is GAAP-loss anyway).
• Dilution machinery: shares 12.0M → 22.4M → 27.9M (FY24→FY25→Q1-26) plus 4.35M pre-funded warrants and ~3.1M public warrants outstanding — relentless issuance is the funding model. This is the primary risk to existing holders even if the company survives.
• Internal controls: risk-factor language warns furloughs "included employees from our accounting department," raising material-weakness risk — a yellow flag on financial-reporting capacity, not (yet) a disclosed material weakness.
• Reverse split: 1-for-15 effective Aug-2024 — a prior cosmetic fix; a second reverse split is now on the table to cure the sub-$1.00 NYSE notice.

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: None. regulatory/regulatory-findings.md reports total_sec_findings: 0 — no LR and no AAER naming ESS Tech in the search window 2021-06-30 → 2026-06-30 (SEC EDGAR EFTS).
• 10-K Item 3 (Legal Proceedings): "The Company is not aware of any material legal proceedings or other claims, legal actions, or complaints through the date of issuance of these financial statements." — clean.
• Non-SEC enforcement (FTC/DOJ/FDA/etc.): web search surfaced no material enforcement actions, fines, or consent decrees against ESS Tech.
• NYSE (listing regulator, not enforcement): two continued-listing deficiency notices — sub-$50M market cap (24-Mar-2025, 18-month cure) and sub-$1.00 average price (9-Jun-2026, 6-month cure). Compliance, not enforcement, but a live delisting risk.
• Net: No material regulatory or legal enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-30. The risk here is survival and listing-compliance, not litigation or fraud.

---

Phase D — Project & stress-test

Forward Projection

This is an operating-variant lens, but for a pre-commercial, going-concern micro-cap the honest projection is scenario-of-survival, not a precise EPS ladder (EPS is meaningless against open-ended dilution). Base year is FY2025 actual; project FY2026–FY2028.

Burn / runway math:

• Cash 31-May-2026: ~$13.6M.
• Operating burn: $(13.5)M in Q1-2026 → ~$4–4.5M/month; ~$8M consumed Mar→May (down from the implied Q1 pace as cost cuts bite, but still severe).
• Runway ≈ 3–4 months of operating cash absent new financing or the EXIM draw. The company must raise within ~one quarter — hence the perpetual ATM/RDO.

Scenario set (no point EPS — dilution path dominates):

• Bear (base-rate likely): Continued ~$45–55M annual burn; sodium-ion "pipeline" does not convert to material revenue in 2026; forced to keep issuing equity at sub-$1 (a second reverse split to cure NYSE) and/or take dilutive convertibles. Equity grinds toward zero / delisting. FY2026 revenue $2–10M, gross still negative. Most-probable path.
• Base: Sodium-ion reseller deals + AFRL/defense produce a step-up to ~$15–40M revenue over FY2026–27, but gross margin stays negative-to-breakeven and the cash gap is bridged only by ongoing dilution. Survives, but shareholders are massively diluted; equity range-bound near survival value.
• Bull: The Alsym sodium-ion channel genuinely lands data-center/utility orders against the "$1B opportunity," ESS becomes a credible non-flammable integrator, a strategic (SoftBank, Honeywell, a hyperscaler, or a sodium-ion consolidator) injects growth capital or acquires it. Revenue scales toward $50M+ by FY2028; equity re-rates multiples from cash-value to a real EV/Sales. Low-probability, high-payoff — the option value.

No our model create (unattended --watchlist rule; and an EPS line would be false precision against open dilution). The scoreable binary, if logged later, is a survival forecast: "GWH avoids delisting AND files a going-concern-qualified-or-better FY2026 10-K as a going concern" — p≈0.4.

Bull vs Bear

Bull case (narrative). ESS owns a genuinely differentiated, non-flammable, critical-minerals-free chemistry validated in the harshest environments on earth (the AFRL/Alaska award is proof). The world needs long-duration and safe storage, and the AI-data-center buildout is creating explosive demand for non-flammable, low-fire-suppression battery systems — exactly what the Alsym sodium-ion partnership targets, with management citing a ~$1B early-stage opportunity pipeline. A capital-markets CEO who can keep the company financed long enough for one of these channels to convert turns a ~$10M shell into a multi-bagger; the cohort leader Eos trades at ~$1.76B, so the ceiling is enormous relative to today's cash-value price. A strategic rescue (SoftBank, Honeywell, a sodium-ion consolidator, or a hyperscaler wanting safe on-site storage) is plausible given the IP and the defense footprint.

Bear case (structural). Three things can permanently impair the equity: (1) The financing runs out or only renews at terms that wipe out existing holders — ~$13.6M cash, ~$4M/month burn, going concern, and a funding model that is literally "sell more stock every quarter." (2) The product never works at commercial economics — a −1,750% gross margin and the discontinuation of the only two products ever sold say the iron-flow flagship has not crossed the cost/reliability threshold after 14 years; the sodium-ion pivot outsources the chemistry to a non-exclusive supplier (Alsym also sells Juniper, etc.), so ESS has no proprietary edge there either. (3) Delisting — sub-$1 and sub-$50M-cap NYSE clocks are both running; a forced second reverse split + delisting risk compounds the dilution death-spiral. Expectations baked into the price: the ~$10M cap implies the market already assigns near-zero probability to commercial success and prices the equity at residual cash — and even that may be optimistic given the burn rate.

Pre-mortem (18 months out, thesis broke). It's end-2027. The sodium-ion "pipeline" never converted to revenue (ESS was just one of several Alsym resellers and lost the real orders to better-capitalized integrators); the company did a second 1-for-X reverse split to stay listed, raised twice more at progressively lower prices, and either delisted to OTC or was acquired for scraps/IP. Existing FY2026 shareholders were diluted 3–5×. The "data-center storage" narrative moved on to incumbents (CATL sodium-ion, Eos, Form Energy).

Are multiples too high? No — multiples are n/m; the equity is priced near cash. The risk is not over-valuation, it is terminal value going to zero via dilution/delisting.

Contrarian view (what the market may be refusing to see). Two-sided. Bear-contrarian: even the ~$10M cash-value price may be too high because the cash is being incinerated and the dilution is structural, so "trades at cash" understates the burn. Bull-contrarian: if you believe the non-flammable / data-center safety thesis and ESS's defense credibility, a ~$10M entry on a name with a $1B-cohort ceiling and a capital-markets CEO whose entire job is engineering a rescue is an asymmetric lottery ticket — but it is a lottery ticket, sized accordingly, not an investment.

Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the model: it already is broken — negative gross margin means the business consumes cash to make product; there is no path to profit without a fundamentally different cost structure the company has not demonstrated in 14 years.
• Revenue concentration: revenue is so small ($1.6M) that it is concentrated in a handful of related-party/demonstration projects (SBE, Honeywell, AFRL). A single cancellation is a material event. The bull "pipeline" is LOIs and "opportunities," not booked, financed orders.
• Why the moat is weaker than bulls think: the prized chemistry has not converted to a single profitable product; the sodium-ion line is licensed-in from Alsym, which sells the same chemistry to ESS's competitors (Juniper) and is building capacity with Re:Build — ESS is a non-exclusive box-assembler, not an IP owner. The defense niche is real but tiny.
• Most dangerous competitor bulls underestimate: not the obvious lithium giants — it's Eos Energy (EOSE), the zinc-based, U.S.-made, non-flammable cohort leader already guiding $300–400M revenue, which occupies precisely the "safe, domestic, non-lithium grid storage" positioning ESS is now chasing with sodium-ion — but with 100×+ the capitalization and a real order book. And CATL/Chinese sodium-ion will commoditize the sodium chemistry ESS is pivoting toward.
• Worst capital-allocation moves: $846M of accumulated deficit for $1.6M of annual revenue; building two EXIM-financed production lines for a product (Energy Base) then reallocating away from it; serial dilution at collapsing prices. Misaligned in effect: the survival imperative forces value-destructive issuance on existing holders.
• Assumptions that must hold for today's price (~$0.8 / ~$10M cap): that the cash isn't fully consumed before a rescue; that NYSE listing is retained; that the sodium-ion narrative attracts a buyer or growth capital. If growth/financing disappoints by even 20–30%, the equity is impaired toward zero — there is no valuation floor below cash because cash is shrinking.
• The single permanent-impairment scenario, and its plausibility: financing dries up / only renews on wipeout terms → bankruptcy or OTC delisting. Plausibility: high on a multi-quarter view absent a transformative event. This is the modal outcome, not the tail.

Management Questions (ordered by information value)

1. With ~$13.6M cash at end-May and ~$4M/month operating burn, what is your specific funded runway to a self-sustaining cash position, and exactly what financing (amount, instrument, dilution) bridges the gap?
2. At a −1,750% gross margin, what is the volume and per-unit cost trajectory at which gross margin turns positive — and what has to be true (chemistry, scale, mix) to get there?
3. The Alsym sodium-ion relationship: is it exclusive to ESS in any market, and what proprietary value does ESS add beyond integration when Alsym sells the same cells to Juniper and others?
4. You discontinued the Energy Warehouse and Energy Center. Will Energy Base ever be productized and sold, or has iron-flow effectively become a defense/niche-only product while sodium-ion becomes the commercial business?
5. What is the probability and timing of a second reverse stock split, and what is the plan if the NYSE sub-$1.00 cure window closes without compliance?
6. Of the "~$1B early-stage opportunities" for sodium-ion, how much is contracted, financed, and revenue-recognizable in the next 12 months — and what is the conversion rate you assume?
7. How do you compete for data-center storage against Eos Energy (already guiding $300–400M, same non-flammable/domestic positioning) and against commoditized Chinese sodium-ion on price?
8. What is the status of the EXIM Bank facility now that capital is being reallocated to sodium-ion — will you draw it, and on what equipment?
9. Given furloughs touched the accounting department, what is the state of internal controls, and do you anticipate a material-weakness disclosure?
10. What strategic alternatives — sale, merger, strategic investment from SoftBank/Honeywell or a hyperscaler — is the board actively evaluating, and on what timeline?
11. What are the warranty / field-performance liabilities on the installed Energy Warehouse/Center fleet, and are reserves adequate?
12. As a capital-markets CEO with no operating/manufacturing background, how is the operating and engineering organization being led, and who owns commercialization?
13. What conditions would trigger a decision to stop funding iron-flow R&D entirely and become a pure sodium-ion integrator?
14. How should shareholders think about further dilution — what is the expected share count 12 and 24 months out under your financing plan?
15. What is the realistic 2027 revenue and gross-margin target, and what are the two or three milestones between now and then that would prove the pivot is working?

---